on PharmaSGP Holding SE (isin : DE000A2P4LJ5)
PharmaSGP Holding SE Holds Annual General Meeting 2025
PharmaSGP Holding SE convened its 2025 Annual General Meeting at its Gräfelfing headquarters, with 91.12% of share capital represented. The company reported a revenue increase of 17.5% in 2024, reaching €118.8 million, and an adjusted EBITDA growth of 9.2% to €37.2 million.
Despite an initial proposal for a €0.51 dividend per share, FUTRUE GmbH proposed and secured approval for a €0.05 dividend. This move aligns with a delisting offer, preserving the offer price of €28 per share without deductions.
The management confirmed a forecast for 2025, anticipating revenues between €122.0 million and €128.0 million, with an adjusted EBITDA forecast from €37.0 million to €39.0 million. In Q1 2025, revenues grew by 10.8% to €33.5 million, with a 4.0% increase in adjusted EBITDA.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PharmaSGP Holding SE news